⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14388431 | 1.00 | — | — | |
| SCHEMBL866068 | 1.00 | — | — | |
| SCHEMBL8186028 | 1.00 | — | — | |
| SCHEMBL8186027 | 1.00 | — | — | |
| SCHEMBL458049 | 1.00 | — | — | |
| SCHEMBL13406449 | 1.00 | — | — | |
| SCHEMBL15703578 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL74585 | 0.98 | GRIK1 (0.66) | — | |
| Hydrochloric Acid SCHEMBL712566 | 0.98 | GRIK1 (0.66) | — | |
| Hydrochloric Acid SCHEMBL713389 | 0.98 | GRIK1 (0.66) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3169403-B9 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | claimed |
| US-20240199700-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-06-20 | — | — | US | claimed |
| EP-4378536-A2 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | Protagonist Therapeutics, Inc. (US) | 2024-06-05 | — | — | EP | claimed |
| EP-3169403-B1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-02-14 | — | — | EP | claimed |
| CN-113563423-A | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel disease | 领导医疗有限公司 | 2021-10-29 | — | — | CN | claimed |
| US-10196424-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2019-02-05 | — | — | US | claimed |
| US-20180022778-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2018-01-25 | — | — | US | claimed |
| EP-3169403-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | Protagonist Therapeutics Inc. (US) | 2017-05-24 | — | — | EP | claimed |
| US-9624268-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-04-18 | — | — | US | claimed |
| US-20160145306-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2016-05-26 | — | — | US | claimed |
| WO-2016011208-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | claimed |
| WO-2004021981-A2 | METHODS FOR THE PREPARATION OF β-AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2004-03-18 | — | — | WO | claimed |
| US-20030113882-A1 | Methods for the preparation of beta-amino acids | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-06-19 | — | — | US | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| EP-4725952-A1 | COMPOUNDS COMPRISING NON-CANONICAL AMINO ACIDS AND USES THEREOF | ETH Zurich (CH) | 2026-04-15 | — | — | EP | disclosed |
| EP-4071477-B1 | COMPOSITIONS AND METHODS FOR DIAGNOSING LYME DISEASE AND FOR PREDICTING LYME DISEASE SPIROCHETE ELIMINATION AFTER TREATMENT | QIAGEN SCIENCES LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20240384267-A1 | COMPOSITIONS AND METHODS FOR MULTIPLEX DECODING OF QUADRUPLET CODONS | THE BROAD INSTITUTE, INC. | 2024-11-21 | — | — | US | disclosed |
| EP-0479897-A1 | ENZYMATICALLY BINDING BIOACTIVE MATERIALS TO PROTEINS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1992-04-15 | — | — | EP | disclosed |
| WO-1991000296-A1 | ENZYMATICALLY BINDING BIOACTIVE MATERIALS TO PROTEINS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1991-01-10 | — | — | WO | disclosed |
| EP-0308983-A2 | NMR imaging with Mn(II) coordination compositions | SALUTAR, INC. (US) | 1989-03-29 | — | — | EP | disclosed |